Table 2.
Characteristics of Survey Respondents Aged 18–65 Diagnosed with Invasive Breast Cancer in Pennsylvania in 2007, stratified by risk of BRCA 1/2 mutation (N=2258)
| Total (N=2258) | High risk (N=546) | Moderate risk (N=852) | Low risk (N=860) | p-value* | |||||
|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | ||
| Age at Diagnosis | |||||||||
| 40 and under | 203 | 9% | 203 | 37% | --- | --- | --- | --- | <0.001 |
| 41 to 50 | 696 | 31% | 264 | 48% | 379 | 44% | 53 | 6% | |
| 51 to 60 | 973 | 43% | 47 | 9% | 349 | 41% | 577 | 68% | |
| 61 to 64 | 386 | 17% | 32 | 6% | 132 | 15% | 222 | 26% | |
|
| |||||||||
| ER/PR positive | 1780 | 79% | 417 | 76% | 648 | 75% | 715 | 84% | <0.001 |
|
| |||||||||
| HER2/neu positive | 387 | 17% | 107 | 20% | 140 | 16% | 140 | 16% | <0.001 |
|
| |||||||||
| Stage at Diagnosis | |||||||||
| Local | 1460 | 65% | 329 | 60% | 587 | 60% | 544 | 64% | 0.051 |
| Regional | 719 | 32% | 198 | 36% | 246 | 29% | 275 | 32% | |
| Distant | 50 | 2% | 13 | 2% | 14 | 2% | 23 | 3% | |
| Unstaged/Unknown | 29 | 1% | 6 | 1% | 13 | 2% | 10 | 1% | |
|
| |||||||||
| Medical oncologist care | |||||||||
| Saw an oncologist and received chemotherapy | 1383 | 61% | 406 | 74% | 529 | 62% | 448 | 53% | <0.001 |
| Saw an oncologist, did not receive chemotherapy | 753 | 33% | 125 | 23% | 285 | 33% | 343 | 40% | |
| Did not see an oncologist, did not receive chemotherapy | 122 | 5% | 15 | 3% | 46 | 5% | 61 | 7% | |
|
| |||||||||
| White | 2026 | 90% | 497 | 91% | 779 | 91% | 771 | 90% | 0.975 |
|
| |||||||||
| Employed | 1243 | 55% | 358 | 66% | 501 | 58% | 384 | 45% | <0.001 |
|
| |||||||||
| Jewish | 134 | 6% | 122 | 22% | 9 | 1% | 3 | 0% | <0.001 |
|
| |||||||||
| Married | 1560 | 69% | 397 | 73% | 580 | 67% | 583 | 68% | 0.099 |
|
| |||||||||
| Educational attainment | |||||||||
| High School or Less | 813 | 36% | 130 | 24% | 342 | 40% | 341 | 40% | <0.001 |
| College (2 or 4 year) | 960 | 43% | 249 | 46% | 373 | 43% | 338 | 40% | |
| Graduate School | 464 | 21% | 164 | 30% | 139 | 16% | 161 | 19% | |
| Missing | 21 | 1% | 3 | 1% | 6 | 1% | 12 | 1% | |
|
| |||||||||
| Annual household income | |||||||||
| <$ 30,000 | 468 | 21% | 83 | 15% | 182 | 21% | 203 | 24% | <0.001 |
| $ 30 001 to $ 70 000 | 776 | 34% | 177 | 32% | 318 | 37% | 281 | 33% | |
| > $ 70 000 | 867 | 38% | 262 | 48% | 316 | 37% | 289 | 34% | |
| Missing | 147 | 7% | 24 | 4% | 44 | 5% | 79 | 9% | |
|
| |||||||||
| Recommendation for BRCA 1/2 testing | |||||||||
| No Recommendation | 1673 | 74% | 255 | 47% | 643 | 75% | 775 | 91% | <0.001 |
| Total Recommended | 585 | 26% | 291 | 53% | 217 | 25% | 77 | 9% | |
| Medical oncologist only† | 186 | 32% | 86 | 30% | 71 | 33% | 29 | 38% | |
| Surgeon only† | 134 | 23% | 64 | 22% | 50 | 23% | 20 | 26% | |
| Both providers† | 265 | 45% | 141 | 49% | 96 | 44% | 28 | 36% | |
|
| |||||||||
| Underwent BRCA 1/2 Testing | 587 | 26% | 290 | 53% | 214 | 25% | 83 | 10% | <0.001 |
*
p-value from chi square test comparing risk groups,
†
Percentage of total recommended